Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of$ 1.70. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -19.41%. A quarter ago, it was expected that this drug developer would post a loss of$ 1.94 per share when it actually produced a loss of $2.05, delivering a surprise of -5.67%. Over the last four quarters, the company has surpasse ...